BCG-CWS联合IL-2预防浅表性膀胱癌术后复发

The clinical use of BCG-CWS and IL-2 for preventing recurrence of superficial bladder cancer

目的 探讨卡介苗细胞壁骨架 (BCG CWS) +白细胞介素 2 (IL 2 )膀胱灌注预防浅表性膀胱癌术后复发的临床效果。方法 5 6例浅表性膀胱癌局部手术后随机分为两组 ,每组 2 8例。分别采用BCG CWS加IL 2和单用丝裂霉素C(MMC)进行膀胱灌注。 结果 5 6例随访 12～ 30个月 ,平均 2 2 .9个月。BCG CWS +IL 2组有 1例肿瘤复发 ,MMC组有 5例肿瘤复发 ,两组肿瘤复发率差别有显著性意义 (P <0 .0 5 ) ;MMC灌注组的毒副反应较BCG CWS +IL 2组多。 结论 BCG CWS联合IL 2预防浅表性膀胱癌术后复发疗效较好 ,副反应少 ,临床使用安全可靠。

Objective To study the therapeutic effects of intravesical instillation of cell wall skeleton of bacillus Calmett Guerin ( BCG CWS ) and interleukin 2 (IL 2 ) in preventing bladder cancers from recurring after local ablation. Methods 56 patients with superficial bladder cancers were randomized in using BCG CWS and IL 2 or MMC for preventing bladder cancers from recurring after local ablation. Results The patients have been followed up for 12～30 months (mean 22.9 months).One patient had tumor recurrence in the group using BCG CWS and IL 2 and five in the MMC group,the rates of tumor recurrence were 3.6%(1/28)and 18.0%(5/28) respectively, and the difference was statistically significant( P <0.05 ). There were obviously more side effects in intravesical instillation with MMC than BCG CWS and IL 2. Conclusions Intravesical instillation of BCG CWS and IL 2 is effective in preventing superficial bladder cancer from recurring after local ablation with fewer adverse effects.The ragimen is not only reliable but also safe.